Genertec Universal Medical Group Company Limited

SEHK:2666 Rapport sur les actions

Capitalisation boursière : HK$8.1b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Genertec Universal Medical Group Croissance future

Future contrôle des critères 2/6

Genertec Universal Medical Group devrait augmenter ses bénéfices et son chiffre d'affaires de 5.9% et de 8.9% par an respectivement. Le BPA devrait croître de de 4.3% par an. Le rendement des capitaux propres devrait être 11.8% dans 3 ans.

Informations clés

5.9%

Taux de croissance des bénéfices

4.3%

Taux de croissance du BPA

Diversified Financial croissance des bénéfices21.7%
Taux de croissance des recettes8.9%
Rendement futur des capitaux propres11.8%
Couverture par les analystes

Low

Dernière mise à jour03 Jul 2024

Mises à jour récentes de la croissance future

Recent updates

Genertec Universal Medical Group's (HKG:2666) Shareholders Will Receive A Bigger Dividend Than Last Year

May 22
Genertec Universal Medical Group's (HKG:2666) Shareholders Will Receive A Bigger Dividend Than Last Year

Genertec Universal Medical Group Company Limited's (HKG:2666) Price Is Right But Growth Is Lacking

May 10
Genertec Universal Medical Group Company Limited's (HKG:2666) Price Is Right But Growth Is Lacking

Why Investors Shouldn't Be Surprised By Genertec Universal Medical Group Company Limited's (HKG:2666) Low P/E

Feb 05
Why Investors Shouldn't Be Surprised By Genertec Universal Medical Group Company Limited's (HKG:2666) Low P/E

Genertec Universal Medical Group (HKG:2666) Is Reducing Its Dividend To CN¥0.34

Jun 08
Genertec Universal Medical Group (HKG:2666) Is Reducing Its Dividend To CN¥0.34

Genertec Universal Medical Group's (HKG:2666) Shareholders Will Receive A Bigger Dividend Than Last Year

Jun 08
Genertec Universal Medical Group's (HKG:2666) Shareholders Will Receive A Bigger Dividend Than Last Year

Genertec Universal Medical Group's (HKG:2666) Shareholders Will Receive A Bigger Dividend Than Last Year

Mar 31
Genertec Universal Medical Group's (HKG:2666) Shareholders Will Receive A Bigger Dividend Than Last Year

Should You Be Adding Genertec Universal Medical Group (HKG:2666) To Your Watchlist Today?

Aug 20
Should You Be Adding Genertec Universal Medical Group (HKG:2666) To Your Watchlist Today?

Here's Why We Think Genertec Universal Medical Group (HKG:2666) Is Well Worth Watching

Apr 19
Here's Why We Think Genertec Universal Medical Group (HKG:2666) Is Well Worth Watching

Shareholders Of Genertec Universal Medical Group (HKG:2666) Must Be Happy With Their 34% Return

Mar 10
Shareholders Of Genertec Universal Medical Group (HKG:2666) Must Be Happy With Their 34% Return

Is Genertec Universal Medical Group Company Limited (HKG:2666) Trading At A 48% Discount?

Feb 19
Is Genertec Universal Medical Group Company Limited (HKG:2666) Trading At A 48% Discount?

Did Genertec Universal Medical Group Company Limited (HKG:2666) Insiders Buy Up More Shares?

Feb 01
Did Genertec Universal Medical Group Company Limited (HKG:2666) Insiders Buy Up More Shares?

The Case For Genertec Universal Medical Group Company Limited (HKG:2666): Could It Be A Nice Addition To Your Dividend Portfolio?

Jan 11
The Case For Genertec Universal Medical Group Company Limited (HKG:2666): Could It Be A Nice Addition To Your Dividend Portfolio?

What Kind Of Investors Own Most Of Genertec Universal Medical Group Company Limited (HKG:2666)?

Dec 21
What Kind Of Investors Own Most Of Genertec Universal Medical Group Company Limited (HKG:2666)?

Reflecting on Genertec Universal Medical Group's (HKG:2666) Share Price Returns Over The Last Three Years

Nov 30
Reflecting on Genertec Universal Medical Group's (HKG:2666) Share Price Returns Over The Last Three Years

Prévisions de croissance des bénéfices et des revenus

SEHK:2666 - Estimations futures des analystes et données financières antérieures (CNY Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/202617,5452,4233,4434,5022
12/31/202516,0472,2612,6273,6053
12/31/202414,5972,1442,2923,2703
12/31/202313,4192,0214,0974,994N/A
9/30/202313,0551,9571,6512,504N/A
6/30/202312,5261,894-76138N/A
3/31/202312,0461,8923441,048N/A
12/31/202211,7301,8881,4142,032N/A
9/30/202211,0181,8821,1691,682N/A
6/30/202210,3051,8759231,333N/A
3/31/20229,9361,855-431-34N/A
12/31/20219,5671,835-1,786-1,401N/A
9/30/20219,3711,870-3,883-3,520N/A
6/30/20219,1751,904-5,980-5,640N/A
3/31/20218,7091,776-3,676-3,306N/A
12/31/20208,2431,648-1,373-972N/A
9/30/20207,8431,5598481,212N/A
6/30/20207,4441,4703,0703,397N/A
3/31/20207,0951,479519786N/A
12/31/20196,7471,489-2,032-1,824N/A
9/30/20196,0711,459-4,512-4,367N/A
6/30/20195,3951,429-6,991-6,909N/A
3/31/20194,8451,390-6,369-6,319N/A
12/31/20184,2951,352-5,746-5,729N/A
9/30/20184,0801,329-6,215-6,198N/A
6/30/20183,8651,305-6,683-6,667N/A
3/31/20183,6451,227-5,887-5,870N/A
12/31/20173,4241,149-5,091-5,072N/A
9/30/20173,2671,105N/A-4,400N/A
6/30/20173,1111,062N/A-3,729N/A
3/31/20172,910967N/A-3,055N/A
12/31/20162,709872N/A-2,382N/A
9/30/20162,587825N/A-2,577N/A
6/30/20162,464778N/A-2,773N/A
3/31/20162,330718N/A-3,613N/A
12/31/20152,195659N/A-4,452N/A
9/30/20152,031605N/A-4,702N/A
6/30/20151,866551N/A-4,951N/A
3/31/20151,711504N/A-4,531N/A
12/31/20141,557457N/A-4,111N/A
12/31/2013984313N/A-4,119N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de 2666 ( 5.9% par an) est supérieure au taux d'épargne ( 2.3% ).

Bénéfices vs marché: Les bénéfices de 2666 ( 5.9% par an) devraient croître plus lentement que le marché Hong Kong ( 11% par an).

Croissance élevée des bénéfices: Les bénéfices de 2666 devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de 2666 ( 8.9% par an) devrait croître plus rapidement que le marché Hong Kong ( 7.4% par an).

Croissance élevée des revenus: Le chiffre d'affaires de 2666 ( 8.9% par an) devrait croître plus lentement que 20% par an.


Prévisions de croissance du bénéfice par action


Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de 2666 devrait être faible dans 3 ans ( 11.8 %).


Découvrir les entreprises en croissance